Wed, Feb 11, 2026
[Archive]
Volume 17, Issue 4 (December-2025 2025)
Iranian Journal of Blood and Cancer 2025, 17(4): 69-81 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sharma S, Singh Matreja P, Singh S, Usha Kiran P. A Meta-Analysis on the Prognostic and Predictive Role of Stem-like CD8+ T Cells in Cancer Immunotherapy: Correlating Clinical Outcomes. Iranian Journal of Blood and Cancer 2025; 17 (4) :69-81
URL: http://ijbc.ir/article-1-1774-en.html
URL: http://ijbc.ir/article-1-1774-en.html
1- Department of Anatomy, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India. , soniyasharma19922@gmail.com
2- Department of Pharmacology, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.
3- Department of Microbiology, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.
4- Department of Biochemistry, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.
2- Department of Pharmacology, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.
3- Department of Microbiology, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.
4- Department of Biochemistry, Teerthanker Mahaveer Medical College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.
Abstract: (14 Views)
Background: Stem-like CD8+ T cells, marked by TCF1 and PD-1, possess self-renewal and effector differentiation abilities, crucial for cancer immunotherapy. Despite tumor microenvironment constraints, their abundance often correlates with favourable outcomes.
Aim: To assess the prognostic and predictive relevance of stem-like CD8+ T cells in patients receiving immunotherapy for cancer.
Methodology: 721 publications from PubMed, Embase, Scopus, and Web of Science (2015–2025) were evaluated in accordance with PRISMA 2020 guidelines. 8 studies were included in the meta-analysis. Two independent reviewers conducted data extraction. Pooled hazard ratios (HRs) and confidence intervals (CIs) were calculated using RevMan software, and the I2 statistic was employed to measure heterogeneity. The ROBINS-I instruments and the Newcastle-Ottawa Scale were used to assess the quality of the study.
Results: 8 of the 13 included papers qualified for meta-analysis. Follow-up periods varied from six months to five years, and sample sizes ranged from 12 to 94 patients. Multiplex immunofluorescence, scRNA-seq, or flow cytometry were used to quantify stem-like CD8+ T cells. Hazard ratios (HRs) in the woodland plot ranged from 1.18 to 28.50. High HRs of 4.31 (95% CI: 2.68–6.92) and 28.50 (95% CI: 3.30–246.15) were observed in two investigations, suggesting a significant adverse prognostic effect. With considerable heterogeneity (I2 = 89%, Chi2 = 61.38, P < 0.00001), the pooled HR was 1.34 (95% CI: 1.22–1.47).
Conclusion: In cancer immunotherapy, stem-like CD8+ T cells serve as both therapeutic targets and significant prognostic indicators. Standardized methods for evaluation and strategies to lessen immunosuppressive effects in the tumor microenvironment are necessary for clinical use.
Aim: To assess the prognostic and predictive relevance of stem-like CD8+ T cells in patients receiving immunotherapy for cancer.
Methodology: 721 publications from PubMed, Embase, Scopus, and Web of Science (2015–2025) were evaluated in accordance with PRISMA 2020 guidelines. 8 studies were included in the meta-analysis. Two independent reviewers conducted data extraction. Pooled hazard ratios (HRs) and confidence intervals (CIs) were calculated using RevMan software, and the I2 statistic was employed to measure heterogeneity. The ROBINS-I instruments and the Newcastle-Ottawa Scale were used to assess the quality of the study.
Results: 8 of the 13 included papers qualified for meta-analysis. Follow-up periods varied from six months to five years, and sample sizes ranged from 12 to 94 patients. Multiplex immunofluorescence, scRNA-seq, or flow cytometry were used to quantify stem-like CD8+ T cells. Hazard ratios (HRs) in the woodland plot ranged from 1.18 to 28.50. High HRs of 4.31 (95% CI: 2.68–6.92) and 28.50 (95% CI: 3.30–246.15) were observed in two investigations, suggesting a significant adverse prognostic effect. With considerable heterogeneity (I2 = 89%, Chi2 = 61.38, P < 0.00001), the pooled HR was 1.34 (95% CI: 1.22–1.47).
Conclusion: In cancer immunotherapy, stem-like CD8+ T cells serve as both therapeutic targets and significant prognostic indicators. Standardized methods for evaluation and strategies to lessen immunosuppressive effects in the tumor microenvironment are necessary for clinical use.
Keywords: Cancer Immunotherapy, CD8 Positive T Lymphocytes, Immunologic Surveillance, Stem Cells, T Cell Exhaustion
: Meta-analysis |
Subject:
Adults Hematology & Oncology
Received: 2025/08/19 | Accepted: 2025/11/8 | Published: 2025/12/30
Received: 2025/08/19 | Accepted: 2025/11/8 | Published: 2025/12/30
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
